Effects of cyclophosphamide combined with prednisone on TNF‑α expression in treatment of patients with interstitial lung disease

Li,Jun; Chen,Xiuling; Qu,Yunping

doi:10.3892/etm.2019.8099

Effects of cyclophosphamide combined with prednisone on TNF‑α expression in treatment of patients with interstitial lung disease

Authors:
- Jun Li
- Xiuling Chen
- Yunping Qu
View Affiliations

Affiliations: Department of Respiratory Medicine, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China, Department of Gynaecology and Obstetrics, First People's Hospital of Jinan, Jinan, Shandong 250014, P.R. China, Department of Stomatology, First People's Hospital of Jinan, Jinan, Shandong 250014, P.R. China
Published online on: October 14, 2019 https://doi.org/10.3892/etm.2019.8099
Pages: 4443-4449
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects of cyclophosphamide combined with prednisone on TNF‑α expression in the treatment of patients with interstitial lung disease (ILD), and its clinical significance were investigated. A prospective analysis was performed on 198 patients with ILD in Jinan Central Hospital Affiliated to Shandong University from January 2010 to December 2017. Among them, 101 patients treated with cyclophosphamide combined with prednisone were assigned in the combined treatment group, and 97 patients treated with prednisone alone in the control group. Patients in the two groups were compared in terms of lung function, St. George's Respiratory Questionnaire (SGRQ) score, clinical efficacy, adverse reactions and TNF‑α expression levels before and after treatment. After treatment, the patients in the combined treatment group had significantly higher forced vital capacity (FVC) and forced expiratory volume in first second (FEV1) compared with the control group, but significantly lower diffusing capacity of lung for carbon monoxide (DLCO) and DLCO% (P<0.05). In both groups, patients after treatment had higher FVC and FEV1, but lower DLCO and DLCO% (P<0.05), compared with before treatment, while SGRQ score before treatment was higher than that after treatment (P<0.05). Compared with control group, the combined treatment group had significantly more patients with complete remission (CR) and higher total effective rate, however less patients with stable disease (SD) (P<0.05). Patients with adverse reactions in the combined treatment group were less than those in the control group (P<0.05). After treatment, TNF‑α expression level in the combined treatment group was significantly lower than that in the control group (P<0.05), and TNF‑α expression before treatment was higher than that after treatment in both groups (P<0.05). In conclusion, cyclophosphamide combined with prednisone is effective and safe in the treatment of ILD without severe adverse reactions, reducing TNF‑α expression level, and therefore is worthy of clinical application.

View Figures

View References

1	Hagmeyer L, Theegarten D, Wohlschläger J, Treml M, Matthes S, Priegnitz C and Randerath WJ: The role of transbronchial cryobiopsy and surgical lung biopsy in the diagnostic algorithm of interstitial lung disease. Clin Respir J. 10:589–595. 2016. View Article : Google Scholar : PubMed/NCBI
2	Anthimopoulos M, Christodoulidis S, Ebner L, Christe A and Mougiakakou S: Lung pattern classification for interstitial lung diseases using a deep convolutional neural network. IEEE Trans Med Imaging. 35:1207–1216. 2016. View Article : Google Scholar : PubMed/NCBI
3	Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR and Ryu JH: Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 164:1182–1185. 2001. View Article : Google Scholar : PubMed/NCBI
4	Salisbury ML, Xia M, Murray S, Bartholmai BJ, Kazerooni EA, Meldrum CA, Martinez FJ and Flaherty KR: Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling. Respir Med. 118:88–95. 2016. View Article : Google Scholar : PubMed/NCBI
5	Johannson KA, Marcoux VS, Ronksley PE and Ryerson CJ: Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and metaanalysis. Ann Am Thorac Soc. 13:1828–1838. 2016.PubMed/NCBI
6	Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, et al: Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 47:588–596. 2016. View Article : Google Scholar : PubMed/NCBI
7	Mathai SC and Danoff SK: Management of interstitial lung disease associated with connective tissue disease. BMJ. 352:h68192016. View Article : Google Scholar : PubMed/NCBI
8	Wallace B, Vummidi D and Khanna D: Management of connective tissue diseases associated interstitial lung disease: A review of the published literature. Curr Opin Rheumatol. 28:236–245. 2016. View Article : Google Scholar : PubMed/NCBI
9	Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Fernandes FB, Casarini DE, Tedesco-Silva H Jr and Medina-Pestana JO: Tacro-limus pharmacokinetic drug interactions: Effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol. 23:137–145. 2009. View Article : Google Scholar : PubMed/NCBI
10	Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, et al international group of investigators; German CLL Study Group (GCLLSG), : First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17:928–942. 2016. View Article : Google Scholar : PubMed/NCBI
11	Reece DE, Trieu Y, Masih-Khan E, Atenafu EG, Chen C, Prica A, Tiedemann R, Trudel S and Kukreti V: Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 16:387–394. 2016. View Article : Google Scholar : PubMed/NCBI
12	He QQ, He X, Wang YP, Zou Y, Xia QJ, Xiong LL, Luo CZ, Hu XS, Liu J and Wang TH: Transplantation of bone marrow- derived mesenchymal stem cells (BMSCs) improves brain ischemia-induced pulmonary injury in rats associated to TNF-α expression. Behav Brain Funct. 12:92016. View Article : Google Scholar : PubMed/NCBI
13	Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR and Garvey C: Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study. Respir Med. 108:203–210. 2014. View Article : Google Scholar : PubMed/NCBI
14	Trudzinski FC, Kaestner F, Schäfers HJ, Fähndrich S, Seiler F, Böhmer P, Linn O, Kaiser R, Haake H, Langer F, et al: Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med. 193:527–533. 2016. View Article : Google Scholar : PubMed/NCBI
15	Volkmann ER and Tashkin DP: Treatment of systemic sclerosis-related interstitial lung disease: A review of existing and emerging therapies. Ann Am Thorac Soc. 13:2045–2056. 2016. View Article : Google Scholar : PubMed/NCBI
16	Hutchinson JP, Fogarty AW, McKeever TM and Hubbard RB: In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 193:1161–1167. 2016. View Article : Google Scholar : PubMed/NCBI
17	Chen H, Zhong JM, Yi ZS, Zha J, Chen Y and Cai LY: Immunological mechanism of prednisone in the treatment of infantile spasm. Zhongguo Dang Dai Er Ke Za Zhi. 19:1044–1050. 2017.(In Chinese). PubMed/NCBI
18	Witt LJ, Demchuk C, Curran JJ and Strek ME: Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 36:46–52. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kundu S, Paul S, Hariprasath K, Agarwal R, Ghosh S and Biswas D: Effect of sequential intravenous pulse cyclophosphamide-azathioprine in systemic sclerosis-interstitial lung disease: An open-label study. Indian J Chest Dis Allied Sci. 58:7–10. 2016.PubMed/NCBI
20	Yunyun F, Yu C, Panpan Z, Hua C, Di W, Lidan Z, Linyi P, Li W, Qingjun W, Xuan Z, et al: Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 7:61952017. View Article : Google Scholar : PubMed/NCBI
21	Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, et al: Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 45:931–943. 2016. View Article : Google Scholar : PubMed/NCBI
22	Mok CC: Con: Cyclophosphamide for the treatment of lupus nephritis. Nephrol Dial Transplant. 31:1053–1057. 2016. View Article : Google Scholar : PubMed/NCBI
23	Gerards MC, Venema GE, Patberg KW, Kross M, Potter van Loon BJ, Hageman IMG, Snijders D, Brandjes DPM, Hoekstra JBL, Vriesendorp TM, et al: Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab. 20:1306–1310. 2018. View Article : Google Scholar : PubMed/NCBI
24	Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, et al Sclerodema Lung Study II Investigators, : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 4:708–719. 2016. View Article : Google Scholar : PubMed/NCBI
25	Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, et al: Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet. 388:2004–2014. 2016. View Article : Google Scholar : PubMed/NCBI
26	Huang AX, Lu LW, Liu WJ and Huang M: Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma - chronic obstructive pulmonary disease (COPD) overlap syndrome. Med Sci Monit. 22:2800–2808. 2016. View Article : Google Scholar : PubMed/NCBI